FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1901-1904 October 28, 2004 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Two thirds of the global population is at risk for malaria. However, about 90 percent of deaths from this disease occur in sub-Saharan Africa, where 1.5 million to 2.5 million of those who die of malaria each year are children. What is more, the incidence of malaria is on the rise — owing in part to the resistance of parasites and mosquitoes to drugs and insecticides and in part to social factors such as migration and political instability. We now know the genomic sequences of the most important malaria parasite of humans (Plasmodium falciparum), the mosquito vector (. . . [Full Text of this Article]

Vector-Targeted Strategies

Strategies Targeting Human Infection

Source Information

From the Center for Microbial and Plant Genomics and the Department of Microbiology, University of Minnesota, St. Paul (K.D.V.); and the Department of Parasitology, Centre of Infectious Diseases, Leiden University Medical Centre, Leiden, the Netherlands (A.P.W.).

This article has been cited by other articles:

• Andrews, K. T., Fairlie, D. P., Madala, P. K., Ray, J., Wyatt, D. M., Hilton, P. M., Melville, L. A., Beattie, L., Gardiner, D. L., Reid, R. C., Stoermer, M. J., Skinner-Adams, T., Berry, C., McCarthy, J. S. (2006). Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria. Antimicrob. Agents Chemother. 50: 639-648 [Abstract] [Full Text]